The compound 2-(2-benzofuranyl)-2-imidazoline (2-BFI) is a 2-imidazoline derivative that selectively inhibits the in vitro activity of monoamine oxidase-A and it is also an imidazoline I 2 agonist. However, the antidepressant potential of this compound and its mechanism of action have not been well defined. Therefore, in this study we investigated the antidepressant-like effect of 2-BFI in mice. 2-BFI (100 and 300 μmol/kg, s.c.) significantly reduced the immobility time on the tail suspension test (TST) without changing locomotion in the open field test. The reduced the immobility time of 2-BFI (100 μmol/kg, s.c.) was confirmed with the forced swimming test (FST). The antidepressant-like effect of 2-BFI (100 μmol/kg, s.c.) in the TST was prevented by pretreatment with idazoxan (0.4 μmol/kg, i.p., a I 2 site antagonist), methysergide (4 μmol/kg, i.p., a non-selective serotonergic receptor antagonist) and haloperidol (0.1 μmol/kg, i.p., a non-selective dopaminergic receptor antagonist). The anxiolytic effect of 2-BFI was also evaluated, using the elevated plusmaze test. 2-BFI (300 μmol/kg, s.c.) was able to significantly increase the % of number of entries and the % of time spent in the open arms, indicating that it possesses an anxiolytic effect at high doses. In conclusion, these results suggest that the antidepressant-like effect of 2-BFI might involve serotonergic, dopaminergic and imidazoline systems, and then the imidazoline site could represent a new pharmacological target for the treatment of depression.
Introduction
The existence of non-adrenoceptor binding sites for imidazol(ine)/guanidine drugs has been shown in various tissues of several species, including the central nervous system (Eglen et al., 1998; Regunathan and Reis, 1996) . Such sites have been separated into at least three entities: the I 1 site, which is found in the brainstem and is associated with blood pressure control (Bousquet et al., 1984) ; the I 2 site that is predominantly found in the brain and liver, where it regulates monoamine turnover (Alemany et al., 1997) ; and the I 3 site, that is located in pancreatic β-cells and regulates insulin secretion (Chan et al., 1994) .
Traditionally, imidazoline I 2 sites have been characterized using the α 2 -adrenoceptor antagonist [ 3 H]-idazoxan in the presence of an α 2 -adrenoceptor masking substance (Michel and Insel, 1989) . However, idazoxan is also an agonist at 5-HT 1A receptors which has limited the characterization of I 2 -imidazoline sites with this drug (Lladó et al., 1996) . Then some ligands have been developed with high selectivity for these sites, notably 2-(2-benzofuranyl)-2-imidazoline (2-BFI) and its quinoline and isoquinoline analogs, 2-(4,5-dihydroimidaz-2-yl)-quinoline (BU224) and 2-(4,5-dihydroimidaz-2-yl)-isoquinoline (BU226) (Lione et al., 1998; Nutt et al., 1995) . 2-BFI has been shown to selectively label imidazoline I 2 sites in mice (Anderson et al., 2006) , rabbit (Lione et al., 1996) and human brains (Wiest and Steinberg, 1997) .
There is evidence that imidazoline I 2 binding sites are allosteric sites located on monoamine oxidase (MAO) (Eglen et al., 1998; Raddatz et al., 1997; Tesson et al., 1991) , an enzyme responsible for the oxidative deamination of neurotransmitters, like serotonin (5-hydroxy tryptamine, 5-HT), noradrenaline and dopamine (DA), and exogenous amines. Moreover, the abnormal function of this enzyme is thought to be involved in several psychiatric disorders, such as depression (Lanni et al., 2009; Manji et al., 2003; Millan, 2004) .
Several imidazoline I 2 ligands have been shown to inhibit MAO activity (Carpéné et al., 1995; Jones et al., 2007; Raasch et al., 1999) . In vitro experiments showed that imidazolines, including 2-BFI and BU224, reversibly inhibit monoamine oxidase A (MAO-A) with a similar potency to that of the reversible MAO-A inhibitor moclobemide (Lalies et al., 1999) . Furthermore, post-mortem studies have shown that the density of I 2 sites was altered in suicide/depressive patients (García-Sevilla et al., 1996 . Probably through this inhibitory action on MAO-A, selective ligands for I 2 sites may possess antidepressant-like properties (Finn et al., 2003) .
Therefore, the aim of the present study was to assess the possible antidepressant-like effect of the 2-imidazoline derivative, 2-BFI, and its mechanism of action in mice.
Materials and methods

Animals
Male Swiss mice (25-30 g) from our own colony were used in this study. Mice were maintained in polycarbonate cages with free access to food and water, on a 12-h alternating light-dark schedule in a temperature-controlled (22 ± 3°C) room. The procedures in this study were performed in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals and approved by the Committee on the Use and Care of Laboratory Animals of our University (Protocol no. 119/2010). For behavioral tests, drugs were administered in random order, and the behavioral measure was carried out by a blinded investigator.
Drugs
2-BFI synthesis was carried out by the method of condensation involving aldehydes and ethylenediamine in the presence of Nbromosucinimide, reaching 100% purity according to analysis of 1 H nuclear magnetic resonance and 13 C nuclear magnetic resonance spectra, as previously reported (Sant'Anna et al., 2009). 2-BFI and diazepam (Compaz®, Cristália, Brazil) were dissolved in a vehicle solution (5% Tween 80, 20% polyethyleneglycol and 75% saline). Idazoxan, methysergide (Sigma Chemical Co., St. Louis, USA) and haloperidol (Haldol®, Janssen-Cilag, Brazil) were dissolved in saline. Injections were performed in a 10 ml/kg volume by the subcutaneous (s.c.) or intraperitoneal (i.p.) route.
Tail suspension test (TST)
The antidepressant-like effect of 2-BFI was measured using the tail suspension test (TST), according to Steru et al. (1985) . Briefly, mice were suspended by their tails using adhesive tape placed approximately 1 cm from the tip of the tail and hung approximately 30 cm above the table. The animals were suspended for 6 min, and the duration of immobility was scored manually during the last 4-min interval of the test. Mice were considered immobile only when they hung passively.
Firstly, a time-course curve was performed. For this, mice were submitted to the TST at 15, 30 and 60 min after the administration of 2-BFI (100 μmol/kg, s.c.) or the vehicle. For the dose-response curve, mice were treated with 2-BFI (30, 100 or 300 μmol/kg, s.c.; equivalent to 6, 19 or 56 mg/kg respectively) or vehicle 30 min before the TST.
To assess the involvement of imidazoline sites, and serotonergic, and dopaminergic receptors in the antidepressant-like effect of 2-BFI, mice received a single injection of idazoxan (0.4 μmol/kg, i.p.; equivalent to 0.1 mg/kg, a I 2 site antagonist), methysergide (4 μmol/ kg, i.p.; equivalent to 2 mg/kg, a non-selective serotonergic receptor antagonist), haloperidol (0.1 μmol/kg, i.p.; equivalent to 0.05 mg/kg, a non-selective dopaminergic receptor antagonist) or saline 15 min (idazoxan) or 30 min (methysergide and haloperidol) before the administration of 2-BFI (100 μmol/kg, s.c.) or vehicle. Thirty minutes after the treatment with 2-BFI or vehicle solution, the animals were submitted to the TST. All doses of antagonists used in this work were chosen according to previous literature data (Duarte et al., 2008; Machado et al., 2007; Rénéric et al.; .
Forced swimming test (FST)
To confirm the antidepressant-like effect of 2-BFI the forced swimming test (FST) was used. Mice were individually forced to swim in an open cylindrical container (diameter 10 cm, height 25 cm), containing 19 cm of water maintained at 25 ± 1°C; the total duration of immobility during the 6-min test was scored as described previously (Zomkowski et al., 2004) . Each mouse was judged to be immobile when it ceased struggling and remained floating motionless in the water, making only those movements necessary to keep its head above water. Mice were submitted to the FST 30 min after the administration of 2-BFI (100 μmol/kg, s.c.) or the vehicle.
Open-field test (OFT)
To assess the possible effects of 2-BFI on locomotor activity, mice were evaluated in the open-field test (OFT), as described previously (Archer, 1973) . The number of crossings was counted in a 5-min session. Mice were injected with 2-BFI (100 or 300 μmol/kg, s.c.) or vehicle 30 min before testing. Another groups of mice were pretreated with idazoxan (0.4 μmol/kg, i.p.), methysergide (4 μmol/kg, i.p.) or haloperidol (0.1 μmol/kg, i.p.) 15 min (idazoxan) or 30 min (methysergide and haloperidol) before the administration of vehicle or 2-BFI (100 μmol/kg, s.c.). Thirty minutes after this treatment, the animals were submitted to the OFT.
Rota-rod test
To evaluate the effect of 2-BFI on motor coordination, the rota-rod test was carried out (Godoy et al., 2004) . The apparatus consisted of a rotatory bar (3.7 cm in diameter) divided into 3 separate compartments that was placed at a height of 25 cm and rotate at a fixed velocity of 8 rpm. The animals were submitted to a training session 24 h before testing. On the test day, mice were injected with 2-BFI (100 or 300 μmol/kg, s.c.) or vehicle 30 min before testing. Another groups of mice were pretreated with idazoxan (0.4 μmol/kg, i.p.), methysergide (4 μmol/kg, i.p.) or haloperidol (0.1 μmol/kg, i.p.) 15 min (idazoxan) or 30 min (methysergide and haloperidol) before the administration of vehicle or 2-BFI (100 μmol/kg, s.c.). Thirty minutes after this treatment, the animals were submitted to the rota-rod test. In the test session, the latency for the first fall and the total number of falls were evaluated during a 4-min period.
Elevated plus maze test
The anxiety-related behaviors were assessed using the mouse elevated plus maze test (Lister, 1987) . The apparatus consists of two open arms (30 × 5 cm) and two enclosed arms (30 × 5 × 15 cm) positioned 40 cm above the floor. The junction of four arms forms a central square platform (5 × 5 cm). Mice received a single administration of 2-BFI (100 or 300 μmol/kg, s.c.) or vehicle 30 min before testing. As a positive control, diazepam (7 μmol/kg, s.c.; equivalent to 2 mg/kg) was administered to mice 30 min before testing (Naderi et al., 2008) . Each animal was placed on the central platform facing one of the open arms and was allowed to explore freely for 5-min. The behavior parameters recorded were the % of number of entries and the % of time spent in the open and closed arms.
Statistical analyses
The results are expressed as the mean ± SEM. Student's t-test and a one-way or two-way analysis of variance (ANOVA) were used to analyze the statistical significance between groups, followed by Bonferroni's or Student-Newman-Keuls' (SNK) post-hoc tests using GraphPad Prism 5.0 software. The level of significance was set at p b 0.05, and only significant results are shown. To meet ANOVA assumptions, haloperidol or vehicle × 2-BFI or vehicle interaction data were subjected to log transformation before statistical analysis.
Results
Fig . 1A shows the time-course curve of 2-BFI (100 μmol/kg, s.c.) on immobility time in the TST. Statistical analysis (two-way ANOVA) showed a significant 2-BFI or vehicle × time interaction [F(1,33) = 3.52; p b 0.01]. Post hoc analysis revealed a 47 ± 7% reduction in immobility time 30 min after 2-BFI administration. Then, a 30-min pretreatment was chosen to carry out the dose-response curve and subsequent experiments. Fig. 1B shows the dose-response curve of 2-BFI (30-300 μmol/kg) on immobility time in the TST. Statistical analysis (one-way ANOVA) revealed that 2-BFI decreased immobility time [F(3,26) = 8.43; p b 0.01]. Post hoc analysis (SNK) showed that 100 and 300 μmol/kg of 2-BFI reduced the immobility time by 41 ± 8% and 53 ± 8% respectively. With the purpose of investigating the mechanisms underlying the antidepressant-like effect of 2-BFI in the TST, mice were pre-treated with idazoxan, methysergide or haloperidol. Fig. 3B ], confirming the suitability of the method used to evaluate anxiety in the present study and suggesting an anxiolytic role for this compound. Diazepam and 2-BFI had no effect on the % of number of entries and the % of time spent in the closed arms (data not shown).
It has been found that compounds that induce changes in locomotor activity can alter the behavioral responses of mice in the TST. Therefore, we investigated the effects of 2-BFI alone and in combination with idazoxan, methysergide or haloperidol on locomotor activity and motor coordination function. The results are shown in Table 1 . The treatment with 2-BFI (100 and 300 μmol/kg, s.c.) did not cause significant alterations in the locomotor ability of the animals, as assessed by the similar number of crossings in the OFT when compared to vehicle. The co-treatment of mice with 2-BFI and idazoxan (0.4 μmol/kg, i.p.), methysergide (4 μmol/kg, i.p.) or haloperidol (0.1 μmol/kg, i.p.) causes no changes on locomotor activity, when compared to saline plus vehicle treated animals. In addition, 2-BFI alone or in combination with antagonists did not significantly affect motor coordination, as assessed by similar fall latencies and total number of falls in the rota-rod when compared to control groups.
Discussion
In the present study, subcutaneous injection of 2-BFI, a 2-imidazoline derivative, decreased the immobility time in the TST, showing an antidepressant-like effect. Previous studies were conflicting on the antidepressant-like potential of imidazoline compounds. O'Neill et al. (2001) demonstrated that selective I 2 receptor ligands (such as BU224) do not show antidepressant-like effects in the FST in BKTO mice. However, Taksande et al. (2009) showed that I 2 receptor ligands (including 2-BFI) were effective in reducing the immobility time in the FST and in potentiating antidepressant-like effects on selective 5-HT reuptake inhibitors in Swiss mice. The differences between these studies may be explained by the differences among I 2 receptor ligands, the test used to detect the antidepressant-like effects and the strain of mice used. 2-BFI, but not BU224, binds with low affinity to α 2 -adrenoceptors (Eglen et al., 1998) . Accordingly, the nature the interaction between the 2-BFI to α 2 -adrenoceptors is still uncertain. Of note, α 2 -adrenoceptors antagonists have antidepressant-like effects (Haddjeri et al., 1995) . Indeed, mirtazapine, a highly potent α 2 -adrenoceptor antagonist, is effect in the treatment of patients with depression (De Boer, 1996) . In addition, an increased level of α 2 -adrenoceptors (31-40%) was found in the prefrontal cortex of depressed patient (García-Sevilla et al., 1999) . Then, if the 2-BFI is interacting as an α 2 -adrenoceptors antagonist, this propriety may, at least in part, explain its effect.
Regarding the test, the TST is the most common animal test specifically used for the screening of new antidepressant drugs because it is easy to execute and highly reliable (Bourin et al., 2005; Cryan et al., 2002) . In this test, mice are exposed to an aversive situation, from which there is no escape, and will, after periods of agitation, cease attempts to escape and become immobile, similar to the immobility observed in the FST (Porsolt et al., 1977; Steru et al., 1985) . Perhaps one of the most important differences between these tests is the apparent higher sensitivity of the TST in detecting the response to drugs (Cryan et al., 2005) . Thus, the better sensitivity of the TST may facilitate the detection of the antidepressant-like effects of I 2 receptor ligands. Finally, there is an important difference in the response to antidepressants between mouse strains, but Swiss mice are most commonly used because they exhibit increased responses to these drugs (Bourin et al., 2005) . As Taksande et al. (2009) , the present study used Swiss mice, which may improve the assessment of the antidepressant-like effects of 2-BFI.
Confirming the results found in TST, 2-BFI decreased the immobility time in the FST. In accordance with Taksande et al. (2009) , that showed that 2-BFI and others I 2 receptor ligands were effective in reducing the immobility time in the FST. Similar to 2-BFI, agmatine, an endogenous ligand at I 1 and I 2 receptors, presented antidepressant and anxiolytic activity in rodents (Aricioglu and Altunbas, 2003; Zomkowski et al., 2002) . Of note, agmatine displaced the binding of [ 3 H]2-BFI to I 2 -imidazoline receptors (Alemany et al., 1997) . In addition, the catabolism of agmatine by agmatinase has recently been found to be increased in post-mortem brains of patients with uniand bipolar disorder (Bernstein et al., 2012) . Thus, with the putative reduction of the endogenous ligand, the use of synthetic I 2 receptor ligands, such as 2-BFI, could be useful in this illness.
Clinical depression in humans is associated with dysregulation or overexpression of imidazoline sites in platelets and brain tissues of depressed patients (García-Sevilla et al., 1999; Holt, 2003; Piletz et al., 2008) . Considering that these sites have a role in mood disorders, the involvement of the imidazoline sites in the antidepressant-like effect of 2-BFI in the TST was studied by using an I 2 antagonist to examine the behavioral responses to 2-BFI (García-Sevilla et al., 1999; Piletz et al., 1996) . Our study showed that the reduction in the immobility time elicited by 2-BFI in the TST was blocked by pretreatment of mice with idazoxan, a preferential imidazoline I 2 receptor antagonist, suggesting the involvement of imidazoline I 2 receptors in the antidepressant-like effect of 2-BFI. Some studies have shown that idazoxan prevented the antidepressant-like effect of desipramine, a noradrenaline reuptake inhibitor, in the FST (Cervo et al., 1990; Rénéric et al., 2001) . Agreeing with the involvement of 2-BFI with imidazoline I 2 receptors, previous studies reporting that [ 3 H]2-BFI bound with higher affinity than [ 3 H]idazoxan, an α 2 -adrenoceptors antagonist traditionally used to characterize I 2 -imidazoline receptors, to a similar number of brain I 2 -imidazoline receptors (Alemany et al., 1997) .
An enzyme that causes oxidative deamination of neurotransmitters like 5-HT, noradrenaline, DA and exogenous amines is the MAO. For decades, the notion that perturbed monoaminergic transmission is causally implicated in depressive states has been enshrined in the literature (Manji et al., 2003) . There is evidence that imidazoline I 2 binding sites are located in MAO (Eglen et al., 1998; Raddatz et al., 1997; Tesson et al., 1991) , and that 2-BFI can inhibit MAO activity in a non-competitive manner (Carpéné et al., 1995) . It was recently shown that 2-imidazoline derivatives showed good potency and selectivity in inhibiting the in vitro activity of MAO in the rat brain (Sant'Anna et al., 2009 ). Among these compounds, 2-BFI showed a great potency to reversibly inhibit the in vitro activity of MAO-A (Lalies et al., 1999; Sant'Anna et al., 2009) . Thus, the antidepressantlike action of 2-BFI could be related to the monoaminergic system owing to its inhibitory effect on MAO activity.
Besides the interaction with imidazoline I 2 site, imidazol(ine) ligands can interact with DA receptors. Sastre-Colla et al. (2001) demonstrated that 2-BFI presents very low affinity for D 2 -dopamine receptors in vitro. However until now, do not have any study showing the affinity of 2-BFI to 5-HT receptors.
It is well known that the 5-HT system plays an important role in the neural regulation of mood (Duman et al., 1997) . The antidepressant drugs used clinically promote an increase in 5-HT and noradrenaline availability at the synaptic cleft (Elhwuegi, 2004) . Some studies have shown the involvement of 5-HT receptors in depression (Pitchot et al., 2005; Svenningsson et al., 2006) . In the present study, we also investigated the involvement of the serotonergic and dopaminergic systems on the antidepressant-like effect of 2-BFI in the TST. The decrease in the immobility time elicited by 2-BFI was reversed by pretreatment of mice with methysergide, a nonselective serotonin receptor antagonist. In the same way, the results demonstrated that haloperidol, a non-selective DA receptor antagonist, significantly antagonized the anti-immobility effect of 2-BFI in mice. These results indicate that the antidepressant-like effect produced by 2-BFI may also involve the serotonergic and dopaminergic systems.
It has been shown that the effects of some antidepressants are prevented by the concurrent administration of a 5-HT 1A receptor antagonist (Detke et al., 1995) . Also, there was a significant hypersensitivity of 5-HT 2 receptors in the brains of depressed suicide victims (Rosel et al., 2000) .
Depressed patients have been reported to have increased DA D 1 / D 2 receptor binding (Shah et al., 1997) and reduced DA transporter activity (Neumeister et al., 2001) . Pharmacological experiments suggest that the DA-like receptors play a key role in the response to biological antidepressant treatments (Lammers et al., 2000; Maj et al., 1996; Rogoz and Dziedzicka-Wasylevska, 1999) .
Some studies have demonstrated that antidepressant agents, including the MAOIs, can also possess anxiolytic properties in different anxiety animal models (De Angelis, 1996; Eroğlu and Güven, 1998) . Thus, to investigate if 2-BFI exerts anxiolytic activity, mice were submitted to the plus maze test, and the results showed that 2-BFI (300 μmol/kg) was able to significantly increase the % of number of entries and the % of time spent in the open arms. These data suggest that 2-BFI, besides producing antidepressant-like effects, may present anxiolytic properties in high doses.
The anti-immobility effect of 2-BFI seems unassociated with alterations on locomotor activity, since mice treated with 2-BFI at doses that were effective in the TST (100 and 300 μmol/kg) did not exhibit increased ambulation when tested in the OFT. The effect of 2-BFI on coordination function was also evaluated using the rota-rod test. No changes in motor coordination activity 30 min after 2-BFI treatment were observed in both 100 and 300 μmol/kg doses. This indicates that a psychostimulant effect is not responsible for the decrease in the immobility elicited by 2-BFI in the TST.
Conclusion
In conclusion, the present results show that 2-BFI presents antidepressant-like effects in mice in both TST and FST. The 2-BFI antidepressant-like effect is reversed by pretreatment with idazoxan, methysergide and haloperidol, suggesting a relationship to the serotonergic, dopaminergic and imidazoline (I 2 receptors) systems. Further studies using other selective or highly specific analytical and pharmacological tools are needed to more reasonably define the role of serotonergic, dopaminergic and imidazoline systems in the antidepressant-like effects of 2-BFI.
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